The “disorderly” delivery that lacks the support of big data in traditional delivery often fails to maximize the effectiveness of advertising. Faced with this problem, JD Marketing 360, based on JD’s data advantages and advanced technical capabilities, launched serialized launch products, and optimized crowd directional circulation, placement channel sequence, and exposure frequency through scientific algorithms, and changed “disorder” to ” Orderly, so as to achieve precise reach and efficient conversion of users.

Accurate crowd + channel strategy to improve advertising efficiency

Regardless of population orientation or channel combination, the formulation of early-stage strategies will undoubtedly have a vital impact on the subsequent delivery process and results, and serialized delivery is currently mainly serving the front link of advertisers from developing marketing strategies to executing marketing plans. . The currently online serialized delivery capabilities support the crowd strategy and channel strategy output before the investment.

In terms of crowd strategy, serialized advertising currently supports diversified scenarios such as new promotion and big promotion/events to meet different marketing goals of brand merchants such as new promotion, cost reduction and efficiency improvement or promotion of conversion efficiency. At the same time, it also provides custom marketing scenarios, provides optimization goals for maximizing GMV or conversion volume, and supports advertisers in DMP custom crowd selection. For different groups of people, serialized delivery will be intelligently divided into potential customers, new customers and regular customers according to their population asset status distribution, combined with different scenarios and optimization goals, to assist in personalized mining channel strategies.

The channel combination applied to serialized delivery currently includes the three major product lines of JD Express, JD booths, and shopping contacts, which can fully cover all reach scenarios in JD.com, and users’ shopping from “shopping” to “buy”. link. In order to achieve more “orderly” delivery, serialized delivery is based on the segmentation of each type of population, and corresponding channel sequences are set up, and the optimal channel combination and contact sequence are used to promote the conversion of the population.

In the channel strategy, serialized delivery can also provide reasonable budget allocation and bid suggestions for each channel, helping advertisers to really spend their budgets on the cutting edge. In addition, serialized placement can also more scientifically control the frequency of placement, and in the process of crowd circulation, the people who have been converted and those who have been exposed more than a certain frequency can be filtered in real time. In this way, at the time of launch, brand merchants can continue to reach people who have met certain exposure frequency requirements and have not converted through subsequent channels, and at the same time screen out over-exposed unwilling purchasers and converted people, reduce invalid exposure, and further improve marketing effectiveness. Help advertisers reduce costs and increase efficiency, increase GMV by nearly 6 times At present, the pre-investment strategy function of serialization has been officially launched under the channel optimization module of JD Marketing 360 Marketing Strategy. Many brands have also taken the lead in using this new function in actual marketing and achieved dazzling marketing effects. In preparation for the JD 618 promotion, OnePlus conducted follow-up investments in JD.com to the crowd exposed by direct investment outside the station during the water storage period of the promotion. When placing on JD.com, use the serialized delivery based on JD’s direct investment to expose the crowd, first conduct the JD Express advertising reach, and then carry out the shopping contact reach of the people who have received at least one exposure and have not converted. Through the AB experiment and unused serialized delivery, based on direct investment to expose the crowd, while comparing the delivery strategies of JD Express and shopping contact delivery, the data shows that serialized delivery is 595% higher than the GMV of non-serialized delivery. ROI increased by 260%, and CPA decreased by 72%, fully verifying that serialized placement can effectively reduce advertising costs and increase efficiency. The launch of serialized launch products adds another weapon to JD Marketing 360’s full cycle, full-link 4E user marketing system. Through scientific and efficient delivery, accurate conversion is obtained, and the entire closed-loop marketing is more perfect. In the future, serialized placement will also provide richer placement strategy support. For example, on the basis of in-site joint investment of advertising business lines such as JD booths, shopping touch points, JD Express, etc., additional investment based on off-site and brand advertising exposure crowds will be added. At the same time, in addition to providing crowd and channel strategy support, it will also provide material strategy assistance, realize the targeted creative delivery of materials and channels according to consumer segmentation behavior, and accelerate the consumption conversion with thousands of people’s material display . Spending the budget in the right place to maximize the value of exposure can be said to be the ideal effect that every advertiser wants to achieve when advertising costs and customer acquisition costs are steadily rising. The launch of JD Marketing 360’s serialized delivery tool allows Advertisers are one step closer to this goal. With the continuous iteration of omni-channel data and technical capabilities of JD Marketing 360, in the future, it will also help more advertisers find an efficient path to business growth and help maximize marketing effectiveness

After interim analysis CureVac defends its vaccine

Status: 06/18/2021 10:19 a.m.

Although an interim analysis of the CureVac vaccine only showed an effectiveness of 47 percent, company boss Haas does not want to know anything about a failure. He is hoping for further tests so that the vaccine will be ready for the market after all. The negative news for the Tübingen company CureVac continues. At first, the company lagged behind the competition in developing its corona vaccine. Then the company went late to the crucial phase 3 to test its vaccine – at that time there were already several variants of the coronavirus. The next bad news followed yesterday: CureVac announced in a mandatory stock market announcement that, according to an interim analysis, its corona vaccine had a preliminary effectiveness of 47 percent against Covid 19 disease “of any severity” have. The value is significantly higher for the other preparations approved in the EU.

“Wild type hardly plays a role anymore”

Company boss Franz-Werner Haas has now gone on the offensive. He defended the company’s corona vaccine against the dpa news agency. No other vaccine has been tested on so many virus variants, he said.

“In fact, it is actually not correct to compare the number of the provisional effectiveness of our corona vaccine and the numbers of the effectiveness of other vaccines”said Haas. The study on the corona vaccine candidate CVnCov contained 29 virus variants. The original virus, the wild type, hardly plays a role anymore. “The efficacy figures for the other vaccines would probably look different if their studies had been carried out at a later date.”

Degree in three weeks

The Tübingen-based company would like to complete the analysis of the data from the final study phase in the next two to three weeks. Haas was convinced that the effectiveness of the vaccine would change again. As soon as this has been completed, CureVac will advise the EMA as to whether further data is required.

The company remains convinced that it will bring its vaccine to approval. According to Haas, even a possibly relatively low effectiveness should not stand in the way. “In view of the pandemic, it can only be said: If there is an effective vaccine, it should also be used.” Haas also referred to the numerous developing countries in which little or no corona vaccines are currently available. The scientific director of the vaccine study at CureVac, Peter Kremsner, believes that it will certainly be possible to make the vaccine operational. In an interview with the BR he said: “That will work for sure. From my point of view, this will not be possible in the next few weeks. But it will be possible to prepare the vaccine so that it can be very effective.”

“It was a noble cause”

The SPD health expert Karl Lauterbach estimates that the setback when entering the market will contribute to the vaccination campaign losing pace for two to three weeks. The promise of the federal government to make a vaccination offer to all adults by the end of the summer is not at risk. “We will reach herd immunity in mid-September”said Lauterbach in the daily topics .

Lauterbach pointed out that the CureVac serum is the “noble” I wanted to be a cheap and very effective vaccine. It would have been predestined for poorer countries. The EU had promised 400 million doses of CureVac to poorer countries. Lauterbach assessed it as a tragedy that this delivery has now been canceled.

No withdrawal of the investor

The announcement of the preliminary effectiveness had caused a drastic plunge in the stock exchange price of CureVac. Investor Dietmar Hopp still believes in the company. He will definitely stay as an investor, he said “Munich Mercury”. He is a firm believer in the company.

The federal government is also holding on to its stake in CureVac, as the Ministry of Economic Affairs said. Last year, he entered CureVac through the KfW development bank with 300 million euros and, according to KfW, holds a share of 16 percent. The federal government has no influence on the operational business, explained the ministry spokeswoman

CureVac Story of a disappointed hope

Status: 06/17/2021 8:30 p.m.

While the world is now being vaccinated with BioNTech, the vaccine from CureVac has proven to be ineffective. How could the two great German hopefuls develop so differently?

By Thomas Aders and Sebastian Deliga, SWR

At first it was a German head-to-head race between the Mainz-based pharmaceutical company BioNTech and the Tübingen researchers from CureVac. Both use the same technology “Messenger RNA”, the share prices of both companies initially took off on the stock exchanges, and both have professional and global partners. The Mainz-based company was able to bring the US pharmaceutical giant Pfizer on board, while the Tübingen-based company found what they were looking for at Bayer. And not only that: At the beginning of September, a man came to visit Tübingen, whose name makes technology enthusiasts, e-mobility enthusiasts and stock market speculators enthusiastic: Tesla boss Elon Musk. Even before he paid his respects to Chancellor Angela Merkel in Berlin, he stopped by CureVac. For the production of their vaccines, the people of Tübingen used the technology of the medium-sized company Grohmann in the Eifel, which in turn has been part of the Tesla empire since 2017.

The field of support from both companies was also in competition: in Tübingen, SAP boss Dietmar Hopp became the majority owner, in Mainz the twins Thomas and Andreas Strüngmann, who had become rich in the pharmaceutical business, and the Bill & Melinda Gates Foundation were behind BioNTech boss Ugur Sahin. From the outside, it was still the duel between digitization pioneer Hopp and oncology professor Sahin. Both were believed to be successful.

But since the beginning of 2021, the people of Baden-Württemberg have stumbled in the race against the Rhineland-Palatinate; while the BioNTech drug was approved by the authorities, CureVac has still not fully completed the third phase of its vaccine testing. Today’s publication of the inferior efficacy of the Tübingen vaccine candidate CVnCOV of only 47 percent – in contrast to 90 percent for BioNTech / Pfizer – was the end of hopes for mass production soon and the end of hopes for strong profits on the stock market; the price of CureVac has more than halved.

Why does the vaccine protect so poorly against Covid-19?

When the Tübingen-based company delayed the crucial phase 3 and tested the vaccine, there were already several mutations of the corona virus. That made research much more difficult. Virologist Martin Stürmer from the University of Frankfurt also sees this as one of the problems: “BioNTech, AstraZeneca and Co. – they only had to deal with B.1.1.7 (the Alpha variant, first developed in England).” In addition, it was the Tübingen’s unwritten law to administer RNA as pure as possible and not chemically treated. This also had fatal consequences for CureVac, because the competition achieved a much higher concentration by modifying the messenger RNA. The head of the CureVac vaccination study, Peter Kremsner: “BioNTech and Moderna were able to dose three to ten times as high because they chemically changed the RNA. At CureVac, the dogma was that the RNA should be injected as unchanged as possible, which is basically correct, but unfortunately it did not work.” The goal of the Tübingen was a noble one. And the SPD politician and epidemiologist Karl Lauterbach is talking about the company’s fate today tagesschau.de “terribly sorry”. He always admired the particularly ethical and moral standards of the Tübingen population. But Lauterbach no longer sees any basis for hope either. Even if CureVac starts all over again, the competitors from BioNTech or Johnson & Johnson, for example, have made further progress in their research. So the Tübingen train left for many.

What does this mean for the vaccination campaign in Germany and Europe?

Epidemiologist Lauterbach very much regrets the bitter fate of CureVac, but he sees the German vaccination campaign as hardly endangered in the Tübingen disaster. Several other vaccines worked to a great extent in his opinion, and in his view today’s setback would result in a delay of no more than three weeks. “By the end of September we will probably have a vaccination rate of 70 percent, and thus herd immunity.” The Federal Ministry of Health is also anything but panicked. Got the latest news about CureVac “no impact on the pace of our vaccination campaign”. Brussels does not want to comment directly on the CureVac disaster, that is a matter for the European Medicines Agency (EMA) in Amsterdam, which decides on the approval of vaccine preparations. However, the EU has apparently taken precautions in the event that CureVac fails: The contract with the Tübingen region includes “Termination clauses in the event that the vaccine is not approved by the EMA”. There are also rather composed comments from Parliament: of course, the results at CureVac are inadequate “a big disappointment”, said MEP Peter Liese. “The goal of offering people in Germany and Europe a vaccination offer by the end of the summer is still realistic.” This is due to the positive developments at BioNTech and Johnson & Johnson. Additional information is interesting in Peter Liese’s statement: CureVac CEO Franz-Werner Haas had already promised him in December that his company would work with other manufacturers, “if your vaccine doesn’t work”. With today’s publication of this conversation note, the pressure on the Tübingen-based company and its partner Bayer should now have increased rapidly to cooperate quickly with successful competitors from Mainz and to convert their own capacities to the production of BioNTech.

Did the state lose money promoting CureVac?

“The federal government is participating in this promising company because it expects it to accelerate developments and to enable CureVac financially to exploit the potential of its technology.” Federal Minister of Economics Peter Altmaier said that almost exactly a year ago. The federal government then invested 300 million euros in the Tübingen-based company. In addition, there was the Federal Ministry of Research, which made a commitment for funding of 251.6 million euros.

All in all, a good half a billion euros. So is the money gone now? The answer: only in part. On the one hand, the federal government received a share in the company for its investment. And although CureVac’s price has slumped by more than half today, the value of that portion is still likely to be significantly higher than when the company went public. And on the other hand, of the promised 251.6 million, only 102.8 million euros have actually flowed so far, as the Ministry of Research tagesschau.de confirmed today. The rest will probably be withheld as the payout “depending on the progress of the project” is. Regardless of the possible “Losses” The question arises, however, what would have happened if the federal government had not invested a cent in promising companies such as CureVac or BioNTech. An outcry would probably have gone through the republic, even though an alleged takeover offer by ex-US President Donald Trump turned out to be a hoax. The situation in the crisis year 2020 was dramatic, according to SPD health expert Lauterbach. “It was an extremely noble attempt by our German companies to develop a new type of Covid vaccine and make it available to the whole world. The investments were right, although in the case of CureVac there was no success.”

Corona vaccine CVnCoV Bad Intermediate result for CureVac

As of: 06/17/2021 6:42 a.m.

Setback for CureVac: The corona vaccine CVnCoV only showed an effectiveness of 47 percent in the second interim analysis, said the Tübingen-based company. The study is to be continued. CureVac’s corona vaccine candidate CVnCoV missed the statistical targets in a second interim analysis. The Tübingen-based company announced this in a mandatory notification. There it says: “In a previously unprecedented environment with at least 13 variants within the subset of study participants examined in this interim analysis, CVnCoV achieved a preliminary effectiveness of 47 percent against COVID-19 disease of any severity and thus did not meet the specified statistical success criteria.” Initial analyzes have shown that the effectiveness depends on the age group examined and the virus strains, the company continues. The vaccine candidate is in the final stage of clinical development. CEO Franz-Werner Haas announced that one had hoped for stronger results in the interim analysis. But continue the current study until the final analysis.

Actually soon approval is planned

Until the beginning of June it had been said that the company expected – depending on the clinical trial data – the approval of its vaccine candidate in the EU at least for the second quarter. But shortly afterwards it became known that the proceedings would be further delayed.

CureVac, which works with Bayer, had long been considered one of the hopes in the competitive race for approval of the first corona vaccines. But while vaccines have been administered by numerous competitors worldwide for months, the Tübingen-based company is still collecting data – and recently had repeatedly put off shareholders and observers.

to step by step formulate many effective economic models, centralized agricultural production areas in the direction of goods, value chains linking people with enterprises.

Mr. Dang Ngoc Hoa’s family (San Que Dong village, Dong Ngu commune, Tien Yen district) changed inefficient rice area to growing fruit trees.

Mr. Dang Ngoc Hoa (San Que Dong village, Dong Ngu commune), is one of the people actively participating in the transformation of crop structure for economic development in the area. Previously, his family mainly cultivated over 5 sao of paddy field with rice and vegetable varieties, but the yield and yield were quite low, due to inadequate irrigation water. 4 years ago, having been facilitated by the commune to participate in training course on fruit growing, with knowledge and techniques learned, Mr. Hoa started to convert old rice and vegetable acreage to fruit tree cultivation. like: Na, orange …

Up to now, his family has more than 70 kernels and 40 oranges for harvesting. Mr. Hoa shared: By converting the cultivars suitable to soil, climate, so the plants grow and develop well, with high and stable fruit yields. Subtracting costs, each year my family has a revenue of hundreds of million dong, much higher than growing rice. From this background, my family continued to plant 50 more super-fruit jackfruit stumps, expected to be harvested in about 2 years …

Similarly, Mr. Nguyen Viet Phuong’s family (Tien Lang commune), is also one of the typical households, taking the lead in changing the structure of livestock in the commune. From small-scale chicken raising, he boldly invested in an integrated farming model combined with acacia plantation for wood. In particular, his farm focuses on breeding and developing native Tien Yen chickens. Currently, his family’s integrated livestock farm has a scale of over 5,000 Tien Yen chickens, nearly 100 pigs and nearly 1 ha of freshwater fish pond, each year bringing his family income from 500-700 million VND. ..

In the past time, in Tien Yen district, many agricultural production households have actively participated in converting plant varieties and animals suitable to local strengths and for high productivity and efficiency. In particular, the district has focused on effectively implementing the project of Agricultural restructuring in the direction of increasing added value and sustainable development, thereby encouraging people to implement crop restructuring. plants and animals associated with the application of science – technology, reorganizing production towards quality and efficiency, focusing on production – business associated with the value chain associated with the consumer market.

In the livestock sector, the district has focused on developing key products through production development support policies. From 2017 up to now, the district has approved and implemented more than 120 livestock support projects. As a result, it has increased from 2 chicken breeding facilities (2015) to 4 (current) facilities with a scale of 5,000 breeding chickens, the ability to provide 350,000 breeds / year. Many households in Tien Yen have gradually shifted from small to small, spontaneous, to livestock based on family size, concentration and commodity nature. Currently, the whole district has 64 certified farms, including: 15 integrated farms, 15 livestock farms, 38 aquaculture and aquaculture farms, 1 forestry farm and 1 crop farm. The whole district has 21 cooperatives, 15 enterprises operating in the agricultural sector.

Promoting the advantage of having a large area of ​​tidal flats, Tien Yen district has focused on attracting investment in the field of aquaculture, developing high-tech aquaculture models, notably the model of technology shrimp farming. . Currently, in the district, there are about 300 households raising technology shrimp, of which 15 households are applying the two-stage vannamei farming model, with concentrated farming areas in Dong Ngu and Dong Hai communes, Hai Lang and Dong Rui. With this area, the district strives for the production value of the fisheries sector to reach more than 493 billion VND, an increase of 13.6% compared to 2020.

In addition, vocational training for rural workers is also focused by the district to help people improve farming skills, as well as measures to prevent and control common diseases on plants and animals. In the 10 years 2010-2020, the whole district has provided vocational training for over 2,000 rural workers, of which 87% of post-trained workers have jobs and stable incomes. From the vocational training courses, many rural laborers in Tien Yen district have actively participated in converting and applying new plant varieties and animals into production practice. Thereby, applying flexibly to practical conditions at households for production and business, contributing to improving the efficiency of agricultural production in the area.